ALT B5
Alternative Names: ALT-B5Latest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Alteogen
- Class Recombinant fusion proteins
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acromegaly
Most Recent Events
- 21 Jan 2025 Alteogen has patent protection for ALT-B5 in USA (Alteogen website; January 2025).
- 01 Jun 2024 Preclinical trials in Acromegaly in South Korea (Parenteral) prior to June 2024
- 01 Jun 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Acromegaly presented at the 106th Annual Meeting of the Endocrine Society (ENDO 2024))